5-bromo-18-methoxy-10-methyl-16-oxa-2,10,21,23-tetraazatetracyclo[15.6.2.0^{3,8}.0^{20,24}]pentacosa-1(23),3,5,7,17,19,21,24-octaene

ID: ALA3109738

Chembl Id: CHEMBL3109738

Cas Number: 807640-87-5

PubChem CID: 11952856

Max Phase: Phase

Molecular Formula: C22H25BrN4O2

Molecular Weight: 457.37

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Jnj-26483327 | JNJ 26483327 | JNJ-26483327 | BGB-102|807640-87-5|JNJ-26483327|CHEMBL3109738|16720VER1H|JNJ 26483327 [WHO-DD]|17-Bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl-4,6-ethenopyrimido(4,5-b)(6,1,12)benzoxadiazacyclopentadecine|4,6-Ethenopyrimido(4,5-b)(6,1,12)benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl-|UNII-16720VER1H|4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoShow More⌵

Canonical SMILES:  COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3

Standard InChI:  InChI=1S/C22H25BrN4O2/c1-27-8-4-3-5-9-29-21-11-17-19(12-20(21)28-2)24-14-25-22(17)26-18-10-16(23)7-6-15(18)13-27/h6-7,10-12,14H,3-5,8-9,13H2,1-2H3,(H,24,25,26)

Standard InChI Key:  JXDYOSVKVSQGJM-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3109738

   JNJ-26483327

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 457.37

Molecular Weight (Monoisotopic): 456.1161

AlogP: 5.14

#Rotatable Bonds: 1

Polar Surface Area: 59.51

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 6.39

CX LogP: 4.70

CX LogD: 4.66

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.55

Np Likeness Score: -0.18

References

1. Giordanetto F, Kihlberg J..  (2014)  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?,  57  (2): [PMID:24044773] [10.1021/jm400887j]

2. Unpublished dataset, 

3. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs.,  358  (6367): [PMID:29191878] [10.1126/science.aan4368]

4. Das D, Hong J..  (2019)  Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.,  170  [PMID:30878832] [10.1016/j.ejmech.2019.03.004]

Source

Source(3):

• Scientific Literature
• Clinical Candidates
• Kuster lab chemical proteomics drug profiling